The long-term objective of the proposed research is to determine the mechanism of action of botulinum toxin, the agent responsible for the disease botulism. As part of this objective, the proposed research will seek ways to prevent the disease and to treat the disease. Most cases of botulism are due to ingestion of food contaminated with pre-formed toxin or to ingestion of food contaminated with bacteria that can produce the toxin in the gut. In either case, botulinum toxin escapes from the gastrointestinal system to reach the general circulation (blood and lymph). Toxin in the blood is then distributed to peripheral cholinergic nerve endings, which are the target cells for toxin action. The toxin enters these cells, where it acts to produce blockade of exocytosis. The progression of events in a typical case of botulism requires that botulinum toxin cross two major cell barriers. First, the toxin must cross from the mucosal to the serosal side of gut endothelial cells. Next, the toxin must penetrate cell membranes and endosomal membranes to reach the cytosol of cholinergic nerves. Therefore the specific aim of the proposed research will be to characterize the mechanisms by which the toxin binds to an penetrates gut and nerve cells. The proposed research will be composed of three major elements. First, the techniques of protein chemistry and molecular biology will be used to generate intact toxin or toxin fragments. Next, human T-84 cells will be used as a model to analyze toxin movement across gut cells. Simultaneously, mouse phrenic nerve-hermidiapragm preparations will be used as a model to assess toxin movement across nerve cells. The results of these experiments will be used to: 1) compare toxin binding and transport in gut and nerve cells, and 2) identify mechanisms for blocking toxin transport in both types of cells.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
3R01NS022153-16S1
Application #
6055090
Study Section
Special Emphasis Panel (ZRG1 (01))
Program Officer
Kitt, Cheryl A
Project Start
1984-09-01
Project End
2003-04-30
Budget Start
1999-05-01
Budget End
2000-04-30
Support Year
16
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Thomas Jefferson University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
061197161
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Xu, Q; Pichichero, M E; Simpson, L L et al. (2009) An adenoviral vector-based mucosal vaccine is effective in protection against botulism. Gene Ther 16:367-75
Ravichandran, Easwaran; Al-Saleem, Fetweh H; Ancharski, Denise M et al. (2007) Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route. Infect Immun 75:3043-54
Zeng, Mingtao; Xu, Qingfu; Elias, Md et al. (2007) Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine. Vaccine 25:7540-8
Ravichandran, Easwaran; Gong, Yujing; Al Saleem, Fetweh H et al. (2006) An initial assessment of the systemic pharmacokinetics of botulinum toxin. J Pharmacol Exp Ther 318:1343-51
Ahsan, Chowdhury R; Hajnoczky, Gyorgy; Maksymowych, Andrew B et al. (2005) Visualization of binding and transcytosis of botulinum toxin by human intestinal epithelial cells. J Pharmacol Exp Ther 315:1028-35
Maksymowych, Andrew B; Simpson, Lance L (2004) Structural features of the botulinum neurotoxin molecule that govern binding and transcytosis across polarized human intestinal epithelial cells. J Pharmacol Exp Ther 310:633-41
Simpson, Lance L; Maksymowych, Andrew B; Park, Jong-Beak et al. (2004) The role of the interchain disulfide bond in governing the pharmacological actions of botulinum toxin. J Pharmacol Exp Ther 308:857-64
Park, Jong-Beak; Simpson, Lance L (2003) Inhalational poisoning by botulinum toxin and inhalation vaccination with its heavy-chain component. Infect Immun 71:1147-54
Park, Jong-Beak; Simpson, Lance L; Anderson, Timothy D et al. (2003) Immunologic characterization of spasmodic dysphonia patients who develop resistance to botulinum toxin. J Voice 17:255-64
Simpson, L L; Maksymowych, A B; Hao, S (2001) The role of zinc binding in the biological activity of botulinum toxin. J Biol Chem 276:27034-41

Showing the most recent 10 out of 42 publications